Cardiac Safety of Methylphenidate Versus Amphetamine Salts in the Treatment of ADHD

Pediatrics

Volumn 124, Issue 1, 2009, Pages

  Winterstein, Almut Gertrud ^a,b   Gerhard, Tobias ^c,d   Shuster, Jonathan ^b   Saidi, Arwa ^e  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d RUTGERS UNIVERSITY   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Amphetamine; Attention deficit hyperactivity disorder; Cardiac events; Central nervous system stimulants; Child and adolescent mental health; Methylphenidate; Pharmacoepidemiology; Psychopharmacology; Safety

Indexed keywords

AMPHETAMINE; ANOREXIGENIC AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; DEXAMPHETAMINE; IPRATROPIUM BROMIDE; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; THEOPHYLLINE DERIVATIVE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR RISK; CHILD; CLINICAL FEATURE; COHORT ANALYSIS; CONGENITAL MALFORMATION; CONTROLLED STUDY; DISABILITY; DRUG EXPOSURE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMERGENCY WARD; FEMALE; FOLLOW UP; GENDER; HEART DISEASE; HOSPITAL ADMISSION; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAID; PHYSICIAN; PRESCHOOL CHILD; PRIORITY JOURNAL; RACE; RETROSPECTIVE STUDY; SCHOOL CHILD; UNITED STATES;

ADOLESCENT; AMPHETAMINE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; FEMALE; HEART; HEART RATE; HUMANS; MALE; METHYLPHENIDATE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 67649615875     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-3138     Document Type: Article

References (14)

1. US Food and Drug Administration. FDA News: FDA Directs ADHD Drug Manufacturers to Notify Patients About Cardiovascular Adverse Events and Psychiatric Adverse Events. Available at: www.fda.gov/bbs/topics/NEWS/2007/ NEW01568.html. Accessed March 14, 2007
2. Samuels JA, Franco K, Wan F, Sorof JM. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol. 2006;21(1):92-95 (Pubitemid 43040200)
3. Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/ hyperactivity disorder. J Clin Psychiatry. 2005;66(2):253-259 (Pubitemid 40314334)
4. Weisler RH, Biederman J, Spencer TJ, Wilens TE. Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10(12 Suppl 20):35-43 (Pubitemid 43010496)
5. Findling RL, Biederman J, Wilens TE, et al. Short-and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr. 2005;147(3):348-354 (Pubitemid 41348714)
6. Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2007;120(6). Available at: www.pediatrics.org/cgi/content/full/120/6/e1494 (Pubitemid 350223669)
7. King S, Griffin S, Hodges Z, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess. 2006;10(23):iii-iv, xiii-146 (Pubitemid 44317375)
8. Gelperin K, Brinker AD, Avigan MI. MedWatch Reporting of Death, Sudden Death, and Cardiovascular Events in Association With Stimulants Used in the Treatment of ADHD Over a Recent 5-Year Period. 2006 FDA Science Forum. Available at: www.cfsan.fda.gov/~frf/forum06/I-04.htm. Accessed July 3, 2006
9. Winterstein AG, Gerhard T, Shuster J, et al. Utilization of pharmacologic treatment in youths with attention-deficit/hyperactivity disorder in Medicaid database. Ann Pharmacother. 2008;42(1):24-31
10. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920 (Pubitemid 37323253)
11. Pelham WE, Aronoff HR, Midlam JK, et al. A comparison of Ritalin and Adderall: efficacy and time-course in children with attention-deficit/ hyperactivity disorder. Pediatrics. 1999;103(4). Available at: www.pediatrics.org/cgi/content/full/103/4/e43
12. Pelham WE, Gnagy EM, Chronis AM, et al. A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 1999;104(6):1300-1311
13. Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics. 1997;100(4):662-666 (Pubitemid 27425991)
14. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr. 2006;27(1):1-10 (Pubitemid 44315107)